Literature DB >> 24122668

Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.

Mehdi Manoochehri1, Ashraf Karbasi, Mojgan Bandehpour, Bahram Kazemi.   

Abstract

Carcinogenesis and resistance to chemotherapy could be as results of expression variations in apoptosis regulating genes. Changes in the expression of apoptosis interfering genes may contribute to colorectal carcinogenesis and resistance to 5-Flourouracil (5-FU) during treatment schedule period. The present study aimed to evaluate the expression of pro-apoptotic and anti-apoptotic genes in colorectal cancer tumor tissues, normal adjacent tissues, and tumor colorectal cancer cell line during acquiring resistance to 5-FU in HT-29 based on Bolus treatment protocol. The normal and tumor tissues were obtained from hospital after surgery and total RNA was extracted for expression analysis. The HT-29 colorectal cancer cell line was cultured and exposed with 5-FU in three stages based on Bolus protocol. The MTT assay and Real Time PCR were carried out to determine the sensitivity to the drug and expression of desired genes, respectively. The obtained data showed that Proapoptotic genes, BAX and BID, were down-regulated in resistant derivate cells compared to wild type HT-29 cells. On the other hand Antiapoptotic genes, CIAP1 and XIAP, showed upregulation in resistant cells compared to wild type ones. Furthermore, BAX and FAS genes showed down-regulation in tumor samples in comparison to normal adjacent tissues. In conclusion, the results of our study suggest that BAX down-regulation could contribute as an important factor during both colorectal carcinogenesis and cell resistance to 5-FU.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24122668     DOI: 10.1007/s12253-013-9695-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  40 in total

1.  Increased burden of colorectal cancer in Asia.

Authors:  Mohamad Amin Pourhoseingholi
Journal:  World J Gastrointest Oncol       Date:  2012-04-15

2.  Screening for dihydropyrimidine dehydrogenase deficiency.

Authors:  Jean L Grem
Journal:  Clin Cancer Res       Date:  2005-07-15       Impact factor: 12.531

3.  State disparities in colorectal cancer mortality patterns in the United States.

Authors:  Deepa Naishadham; Iris Lansdorp-Vogelaar; Rebecca Siegel; Vilma Cokkinides; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07       Impact factor: 4.254

Review 4.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

5.  Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression.

Authors:  Seungho Choi; Ja-Lok Ku
Journal:  Biochem Biophys Res Commun       Date:  2011-07-22       Impact factor: 3.575

6.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

Authors:  P Piedbois; P Rougier; M Buyse; J Pignon; L Ryan; R Hansen; B Zee; B Weinerman; J Pater; C Leichman; J Macdonald; J Benedetti; J Lokich; J Fryer; G Brufman; R Isacson; A Laplanche; E Levy
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

7.  Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.

Authors:  Walid Shaib; Veronica Lee; M Wasif Saif
Journal:  In Vivo       Date:  2009 Sep-Oct       Impact factor: 2.155

Review 8.  Aetiology of cancer in Asia.

Authors:  Sohee Park; Jisuk Bae; Byung-Ho Nam; Keun-Young Yoo
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jul-Sep

9.  Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling.

Authors:  Wolfgang M Schmidt; Maria Kalipciyan; Eva Dornstauder; Blanka Rizovski; Guenther G Steger; Roland Sedivy; Manfred W Mueller; Robert M Mader
Journal:  Int J Cancer       Date:  2004-11-01       Impact factor: 7.396

10.  Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.

Authors:  Christian N Arnold; Ajay Goel; C Richard Boland
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

View more
  11 in total

Review 1.  Direct Activation of Bax Protein for Cancer Therapy.

Authors:  Zhiqing Liu; Ye Ding; Na Ye; Christopher Wild; Haiying Chen; Jia Zhou
Journal:  Med Res Rev       Date:  2015-09-23       Impact factor: 12.944

2.  Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.

Authors:  Melanie Arul; April Camilla Roslani; Swee Hung Cheah
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-01-24       Impact factor: 2.416

3.  Promoter hypermethylation and downregulation of the FAS gene may be involved in colorectal carcinogenesis.

Authors:  Mehdi Manoochehri; Nasim Borhani; Ashraf Karbasi; Ameneh Koochaki; Bahram Kazemi
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

4.  Knockdown of PHGDH potentiates 5-FU cytotoxicity in gastric cancer cells via the Bcl-2/Bax/caspase-3 signaling pathway.

Authors:  Yunli Zhang; Litao Yang; Guangou Dai; Hu Cao
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

5.  Methylation of Promoters of Apoptosis-Related Genes in Blood Lymphocytes of Workers Exposed to Occupational External Irradiation.

Authors:  D S Isubakova; O S Tsymbal; E V Bronikovskaya; N V Litviakov; I V Milto; R М Takhauov
Journal:  Bull Exp Biol Med       Date:  2021-07-23       Impact factor: 0.804

6.  Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.

Authors:  Huei-Yu Chen; Atikul Islam; Tien-Ming Yuan; Shi-Wen Chen; Pei-Fen Liu; Pin Ju Chueh
Journal:  J Exp Clin Cancer Res       Date:  2018-07-20

Review 7.  Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.

Authors:  Manzar Alam; Shoaib Alam; Anas Shamsi; Mohd Adnan; Abdelbaset Mohamed Elasbali; Waleed Abu Al-Soud; Mousa Alreshidi; Yousef MohammedRabaa Hawsawi; Anitha Tippana; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

Review 8.  Emerging actionable targets to treat therapy-resistant colorectal cancers.

Authors:  Emanuela Grassilli; Maria Grazia Cerrito
Journal:  Cancer Drug Resist       Date:  2022-01-04

9.  Association between SET expression and glioblastoma cell apoptosis and proliferation.

Authors:  Kunyan He; Lihong Shi; Tingting Jiang; Qiang Li; Yao Chen; Chuan Meng
Journal:  Oncol Lett       Date:  2016-08-03       Impact factor: 2.967

Review 10.  Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.

Authors:  Jose J G Marin; Rocio I R Macias; Maria J Monte; Elisa Herraez; Ana Peleteiro-Vigil; Beatriz Sanchez de Blas; Paula Sanchon-Sanchez; Alvaro G Temprano; Ricardo A Espinosa-Escudero; Elisa Lozano; Oscar Briz; Marta R Romero
Journal:  Cancers (Basel)       Date:  2020-09-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.